Kronos Bio Inc (KRON) Stock Price, Quote & News

Company Profile

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT inhibitor, which is in preclinical development for the treatment of Sjogren's disease. The company was...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 781 5200

Website: www.kronosbio.com

Address:

1300 So. El Camino Real, Suite 400, San Mateo, United States

TwongStocks Jun. 16 at 8:53 PM

$KRON NASDAQ Equity Corporate Actions Alert # 2025 - 314 Information Regarding the Tender Offer of Kronos Bio, Inc. (KRON) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-314 The tender offer by Concentra Biosciences, LLC to acquire all of the outstanding common stock of Kronos Bio, Inc. (KRON) is scheduled to expire one minute after 11:59 p.m. ET, on June 18, 2025, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on June 20, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on June 18, 2025. If the merger closes as planned, the stock will remain halted on the day of closing (June 20) and will be suspended effective June 23, 2025. Merger consideration is $0.57 per share plus CVRs.

0 · Reply

11thestate Jun. 16 at 11:44 AM

$KRON stockholders filed a claim against Kronos Bio for allegedly misleading investors about its merger with Concentra and withholding key financial details. You can join this case to be notified about any new information: https://11th.com/cases/kronos-investor-suit

0 · Reply

ShortSqueeze10X Jun. 6 at 7:56 PM

$NEGG $KRON $SMGT $EYEN Monday continuation run $CRON 3 day hold

0 · Reply

PenkeTrading Jun. 6 at 10:10 AM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Kronos Bio Inc. Is that bullish or bearish? $KRON #RsiOverbought #NASDAQ

0 · Reply

kebrik Jun. 5 at 1:40 PM

Today's movers: $HOTH, $MODV, $RVYL, $KRON, and $CMND

0 · Reply

topstockalerts Jun. 5 at 12:42 PM

Pre Market Top Gainers PT2 $ZJK $CTNT $KRON $BWNB

0 · Reply

LAF1 Jun. 5 at 12:36 PM

$KRON setting up for bullish Run $STOCKTWITS

0 · Reply

dbr_island Jun. 5 at 12:11 PM

$KRON $SLNH $BANL $MCTR $MKDW let’s all bank hard today $ZBAI anyone here have at least 40,000 shares? This is why smart money has been loading👇🙏

1 · Reply

Stmkr Jun. 5 at 12:07 PM

$KRON Thank you KRON. I am out now. Good luck to those holding for the rest of the CRVs

0 · Reply

HorsePicks Jun. 5 at 11:55 AM

$KRON Kronos Bio Terminated 301 Binney Street Lease, Will Pay $22.5M Termination Fee, Expects $18.2M in Cost Savings

0 · Reply

KRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRON

May 1, 2025, 8:30 AM EDT - 6 weeks ago

Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right

Mar 18, 2025, 4:01 PM EDT - 3 months ago

Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results

Nov 27, 2024, 7:30 AM EST - 7 months ago

Kronos Bio Announces CEO Transition and Reduction in Force

Nov 14, 2024, 4:02 PM EST - 7 months ago

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

Oct 23, 2024, 8:55 AM EDT - 8 months ago

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors

Oct 9, 2024, 8:55 AM EDT - 8 months ago

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors

Oct 7, 2024, 8:55 AM EDT - 9 months ago

Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease

Sep 25, 2024, 8:55 AM EDT - 9 months ago

Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy

Sep 23, 2024, 8:55 AM EDT - 9 months ago

Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer

Sep 3, 2024, 8:55 AM EDT - 10 months ago

Kronos Bio Announces Participation in Medical and Investor Conferences in September

Jul 23, 2024, 4:15 PM EDT - 11 months ago

Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer

May 23, 2024, 5:15 PM EDT - 1 year ago

Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2024, 4:30 PM EDT - 1 year ago

Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events

May 21, 2024, 8:15 AM EDT - 1 year ago

Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer

May 9, 2024, 4:05 PM EDT - 1 year ago

Kronos Bio Reports First-Quarter 2024 Financial Results

May 6, 2024, 6:40 PM EDT - 1 year ago

Kronos Bio: Underestimated Drug Discovery Platform

Mar 21, 2024, 7:05 AM EDT - 1 year ago

Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results

Mar 12, 2024, 8:00 AM EDT - 1 year ago

How Does Kronos Stock Look After Its 15% Rise Last Week?

Mar 7, 2024, 4:05 PM EST - 1 year ago

Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway

Mar 5, 2024, 4:44 PM EST - 1 year ago

Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting

Feb 27, 2024, 4:05 PM EST - 1 year ago

Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference

Jan 25, 2024, 8:00 AM EST - 1 year ago

Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement

Dec 18, 2023, 4:06 PM EST - 1 year ago

Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate

Dec 4, 2023, 8:00 AM EST - 1 year ago

Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Nov 27, 2023, 4:05 PM EST - 1 year ago

Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference

Nov 13, 2023, 4:05 PM EST - 1 year ago

Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results

Nov 2, 2023, 4:05 PM EDT - 1 year ago

Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study

Nov 2, 2023, 12:00 PM EDT - 1 year ago

Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting

Oct 27, 2023, 8:00 AM EDT - 1 year ago

Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting

Oct 13, 2023, 12:30 PM EDT - 1 year ago

Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC

Oct 4, 2023, 4:05 PM EDT - 1 year ago

Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13

Aug 17, 2023, 8:00 AM EDT - 1 year ago

Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate Development

Aug 8, 2023, 4:05 PM EDT - 2 years ago

Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial Results

Jun 6, 2023, 8:00 AM EDT - 2 years ago

Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance

Jun 1, 2023, 4:05 PM EDT - 2 years ago

Kronos Bio Announces Participation in Upcoming Investor Conferences

May 10, 2023, 4:05 PM EDT - 2 years ago

Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results

Apr 24, 2023, 4:05 PM EDT - 2 years ago

Kronos Bio Appoints Roger Dansey, M.D., to Board of Directors

Apr 11, 2023, 4:05 PM EDT - 2 years ago

Kronos Bio Announces Changes to Board of Directors

Mar 15, 2023, 4:05 PM EDT - 2 years ago

Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2022 Financial Results

Feb 28, 2023, 4:05 PM EST - 2 years ago

Kronos Bio Announces Participation in 43rd Annual Cowen Health Care Conference

Jan 9, 2023, 8:23 AM EST - 2 years ago

Kronos Bio's stock rallies after announcing drug-discovery deal with Roche

Jan 9, 2023, 7:00 AM EST - 2 years ago

Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology

Dec 11, 2022, 10:00 AM EST - 2 years ago

Kronos Bio Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in Combination with Multiple Targeted Agents in Acute Myeloid Leukemia (AML) Preclinical Models at American Society of Hematology Meeting

Dec 7, 2022, 4:05 PM EST - 2 years ago

Kronos Bio Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1/2 Clinical Trial

Nov 8, 2022, 4:10 PM EST - 2 years ago

Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial Results

Nov 8, 2022, 4:05 PM EST - 2 years ago

Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742

Oct 12, 2022, 4:04 AM EDT - 2 years ago

Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Pediatric Cancer Models in Poster Presentation at EORTC-NCI-AACR 2022

TwongStocks Jun. 16 at 8:53 PM

0 · Reply

11thestate Jun. 16 at 11:44 AM

0 · Reply

ShortSqueeze10X Jun. 6 at 7:56 PM

$NEGG $KRON $SMGT $EYEN Monday continuation run $CRON 3 day hold

0 · Reply

PenkeTrading Jun. 6 at 10:10 AM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Kronos Bio Inc. Is that bullish or bearish? $KRON #RsiOverbought #NASDAQ

0 · Reply

kebrik Jun. 5 at 1:40 PM

Today's movers: $HOTH, $MODV, $RVYL, $KRON, and $CMND

0 · Reply

topstockalerts Jun. 5 at 12:42 PM

Pre Market Top Gainers PT2 $ZJK $CTNT $KRON $BWNB

0 · Reply

LAF1 Jun. 5 at 12:36 PM

$KRON setting up for bullish Run $STOCKTWITS

0 · Reply

dbr_island Jun. 5 at 12:11 PM

$KRON $SLNH $BANL $MCTR $MKDW let’s all bank hard today $ZBAI anyone here have at least 40,000 shares? This is why smart money has been loading👇🙏

1 · Reply

Stmkr Jun. 5 at 12:07 PM

$KRON Thank you KRON. I am out now. Good luck to those holding for the rest of the CRVs

0 · Reply

HorsePicks Jun. 5 at 11:55 AM

$KRON Kronos Bio Terminated 301 Binney Street Lease, Will Pay $22.5M Termination Fee, Expects $18.2M in Cost Savings

0 · Reply

Justgivememymoney Jun. 5 at 11:51 AM

$KRON going over a dollar 💪🏼

0 · Reply

tyrus6 Jun. 5 at 11:48 AM

$KRON Lowball buyout offer of 57 cents a share but it's trading higher. https://www.sec.gov/Archives/edgar/data/1741830/000114036125021481/ny20048795x2_exa1a.htm

0 · Reply

topstockalerts Jun. 5 at 11:35 AM

Pre Market Top Gainers PT2 $RGC $KRON $PHIO $CGTX $PL

0 · Reply

intrader Jun. 5 at 11:24 AM

$KRON I'm out. 9% gain.

0 · Reply

AKtrader9958 Jun. 5 at 11:15 AM

$KRON any news?

0 · Reply

Dusty_Bunz May. 13 at 2:46 AM

$KRON 👀

0 · Reply

joe77w May. 5 at 4:55 PM

$KRON non tradeable

0 · Reply

RandRap May. 5 at 10:15 AM

$KRON Does anyone know if the CVR will be tradable in an exchange?

0 · Reply

smartkarma May. 2 at 10:53 AM

$KRON | Weekly Financial Insights: KRON Buyout, SAGE Earnings, BOOM Performance and More "Kronos Bio (KRON) signed an acquisition agreement at $0.57/share plus a CVR, below expected net cash value. Sage Therapeutics (SAGE) reported Q1 revenue growth..." - Special Situation Investments (Special Situation Investments) Read more: https://www.smartkarma.com/insights/weekly-financial-insights-kron-buyout-sage-earnings-boom-performance-and-more

0 · Reply

smartkarma May. 2 at 10:42 AM

$KRON | KRON Acquisition by Kevin Tang: Analyzing the CVR Structure and Potential Shareholder Value Outcomes "KRON is being acquired at $0.57/share plus a CVR, below expected net cash of $1/share. The CVR includes four components, with..." - Special Situation Investments (Special Situation Investments) Read more: https://www.smartkarma.com/insights/kron-acquisition-by-kevin-tang-analyzing-the-cvr-structure-and-potential-shareholder-value-outcomes

0 · Reply

Jalard May. 2 at 4:27 AM

$KRON is this a good short sell for a intrady trade?

0 · Reply

Stmkr May. 1 at 7:22 PM

$KRON So if I buy now (at $0.7), at the closing of the merger I am getting back 80% of the money ($0.57). So I lose 20% but the rest 80% are free for re-investment and still have the CVR potential whith good chances of at the least breaking even + good upside potential if a good deal comes for their assets. Just the net cash above $40M at closing should be sufficient to at the least break even. Am I getting this wrong??

1 · Reply

Market Cap	54.49M
Revenue (ttm)	9.85M
Net Income (ttm)	-86.08M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-873.91%
Debt to Equity Ratio	0.00

Volume	1,192,400
Avg Vol	958,910
Day's Range	N/A - N/A
Shares Out	61.05M
Stochastic %K	66%
Beta	1.63
Analysts	Strong Sell
Price Target	$2.25